Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Riddhima Chakraborty

BIZARRE: 2 biotech stock to buy over moderna this december | Mind Blowing Facts

Biotech giant Moderna, Inc. (MRNA) missed consensus revenue and EPS estimates by 4.6% and 18.6%, respectively, for its third quarter that ended September 30, 2022. Its total revenue came in at $3.36 billion, down 32.3% year-over-year, and its EPS came in at $2.53, down 67.1% year-over-year.

Moreover, its revenue and EPS are expected to decline 32.6% and 57.5% year-over-year to $4.86 billion and $4.80 for the quarter ending December 2022. In addition, the stock has lost 21.7% over the past year and 17.3% year-to-date.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.